经尿道前列腺电切术史患者接受极限或中度大分割前列腺放疗后的晚期泌尿毒性
本研究纳入203例有经尿道前列腺电切术(TURP)史的前列腺癌患者,分别接受中度大分割放疗(MHRT,114例,64-68 Gy/25次)或极限大分割立体定向体部放疗(SBRT,89例,35-37.5 Gy/5次)。中位随访37个月,累积3级和2级晚期泌尿毒性分别为8.4%和23.2%,多因素分析未发现与晚期2级以上泌尿毒性显著相关的因素。
要点
- 有TURP史患者接受大分割前列腺放疗后,3级晚期泌尿毒性累积发生率为8.4%。
- 3级症状主要为血尿(6.4%)和尿路梗阻(3.4%),中位持续8个月。
- 多因素分析未发现年龄、糖尿病、分割剂量等因素与晚期2级以上泌尿毒性显著相关。
核心结论
- 在有TURP史并接受大分割前列腺放疗的大样本队列中,严重晚期泌尿不良反应发生率低于10%,主要为血尿或尿路梗阻,且多为暂时性,未发现显著 contributory 因素。
研究设计与样本
- 研究纳入诊断为前列腺癌、有TURP史并接受中度大分割调强放疗(MHRT)或极限大分割立体定向体部放疗(SBRT)的患者,数据来自前瞻性维护的机构数据库。
- 共纳入203例 eligible 患者,其中MHRT组114例(64-68 Gy/25次),SBRT组89例(35-37.5 Gy/5次)。
主要发现
- TURP至放疗的中位时间为10个月(IQR 7-16个月),MHRT组与SBRT组相似。
- 总体腔体积平均为1.17 cc(IQR 0.5-1.35 cc),MHRT组为1.03 cc(IQR 0.4-1.15 cc),SBRT组为1.27 cc(IQR 0.5-1.4 cc)。
- 中位随访37个月时,累积3级和2级晚期泌尿毒性分别为8.4%(n=17)和23.2%(n=47)。
- 3级症状在放疗完成后中位29个月(IQR 19-62个月)出现,中位持续8个月(IQR 2-14个月);主要3级症状为血尿(6.4%)和尿路梗阻(3.4%)。
- 对年龄、糖尿病、盆腔放疗、分割剂量、前列腺体积、TURP至放疗间隔时间及TURP腔体积的多因素分析显示,均与晚期2级以上泌尿毒性无显著关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To study the late urinary toxicity in patients with prostate cancer with prior transurethral resection of prostate (TURP) and treated with hypofractionated prostate radiation therapy. METHODS AND MATERIALS: Patients diagnosed with prostate cancer, with a prior TURP, and treated with moderate or extreme hypofractionated intensity-modulated radiation therapy (moderate hypofractionated radiation therapy [MHRT], stereotactic body radiation therapy [SBRT]), were included in this study. Severity and duration of urinary symptoms observed during serial follow-up after at least 3 months from radiation therapy were graded per National Cancer Institute Common Terminology Criteria for Adverse Events v5.0 using information from a prospectively maintained institutional database. Impact of hypofractionation and other potential contributory factors on cumulative grade 2+ late urinary toxicity was analyzed with univariable and multivariable binary logistic regression. RESULTS: A total of 203 eligible patients were included (MHRT = 114, 64-68 Gy/25#; SBRT = 89, 35-37.5 Gy/5#). Median time from TURP to radiation therapy was 10 months (IQR, 7-16 months), similar for MHRT and SBRT. Overall, mean cavity volume was 1.17 cc (IQR, 0.5-1.35 cc), whereas in MHRT and SBRT groups it was 1.03 cc (IQR, 0.4-1.15 cc) and 1.27 cc (IQR, 0.5-1.4 cc), respectively. At a median follow-up of 37 months, cumulative grade 3 and grade 2 late urinary toxicity was 8.4% (n = 17) and 23.2% (n = 47), respectively. Grade 3 symptoms were observed at median 29 months (IQR, 19-62 months) after radiation therapy completion, lasting for a median duration of 8 months (IQR, 2-14 months). Hematuria (6.4%) and urinary obstruction (3.4%) were the chief grade 3 symptoms. Multivariable analysis for age, diabetes, pelvic radiation therapy, fraction size, prostate volume, TURP to radiation therapy duration, and TURP cavity volume showed no significant association with late grade 2+ urinary toxicity. CONCLUSIONS: In this large cohort of patients with prior TURP and treated with hypofractionated prostate radiation therapy, incidence of severe late urinary adverse effects was <10%, mainly hematuria or urinary obstruction. Most of these were temporary, and no significant contributory factors were identified for late urinary morbidity after TURP and radiation therapy.
引用
- Singh M, Maitre P, Krishnan A, et al. Late Urinary Toxicity After Extreme or Moderate Hypofractionated Prostate Radiation Therapy in Patients With Prior Transurethral Resection of Prostate. Int J Radiat Oncol Biol Phys. 2024. PMID: 38908410. doi:10.1016/j.ijrobp.2024.06.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。